Humacyte stock falls 6% on public offering announcement

Humacyte experienced a decline of 6% in its stock price following the announcement of a public offering. The decision to proceed with the offering has raised concerns among investors, leading to a decrease in market confidence. The company's move is part of its strategy to raise capital, although the immediate reaction from the market has been negative.

Read More